Neurosense Therapeutics Ltd Stock Performance
| NRSNW Stock | USD 0.21 0.01 5.00% |
NeuroSense Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.87, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning NeuroSense Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, NeuroSense Therapeutics is expected to outperform it slightly. Use NeuroSense Therapeutics sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on NeuroSense Therapeutics.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NeuroSense Therapeutics Ltd are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, NeuroSense Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3.5 M |
NeuroSense |
NeuroSense Therapeutics Relative Risk vs. Return Landscape
If you would invest 36.00 in NeuroSense Therapeutics Ltd on December 5, 2024 and sell it today you would lose (15.00) from holding NeuroSense Therapeutics Ltd or give up 41.67% of portfolio value over 90 days. NeuroSense Therapeutics Ltd is currently producing 2.5508% returns and takes up 26.74% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than NeuroSense, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NeuroSense Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeuroSense Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeuroSense Therapeutics Ltd, and traders can use it to determine the average amount a NeuroSense Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0954
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NRSNW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 26.74 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.55 actual daily | 50 50% of assets have lower returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average NeuroSense Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeuroSense Therapeutics by adding it to a well-diversified portfolio.
NeuroSense Therapeutics Fundamentals Growth
NeuroSense Stock prices reflect investors' perceptions of the future prospects and financial health of NeuroSense Therapeutics, and NeuroSense Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeuroSense Stock performance.
| Return On Equity | -4.95 | ||||
| Return On Asset | -2.2 | ||||
| EBITDA | (10.63 M) | ||||
| Cash And Equivalents | 994 K | ||||
| Cash Per Share | 0.13 X | ||||
| Total Debt | 142 K | ||||
| Book Value Per Share | (0.14) X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Earnings Per Share | (0.94) X | ||||
| Total Asset | 3.18 M | ||||
| Retained Earnings | (32.07 M) | ||||
About NeuroSense Therapeutics Performance
Evaluating NeuroSense Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NeuroSense Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NeuroSense Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics is traded on NASDAQ Exchange in the United States.Things to note about NeuroSense Therapeutics performance evaluation
Checking the ongoing alerts about NeuroSense Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeuroSense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. |
- Analyzing NeuroSense Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeuroSense Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining NeuroSense Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeuroSense Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeuroSense Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeuroSense Therapeutics' stock. These opinions can provide insight into NeuroSense Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.